Effectiveness of Unified Transdiagnostic Protocol in psychosomatic symptoms in patients with Multiple Sclerosis: A randomized controlled trial

Amir Mahdi Katani¹, Abbas Masjedi Arani², Reza Hajmanouchehri³, Banafsheh Mohajerin⁴

ABSTRACT

Introduction: Psychologically-driven manifestations, including psychosomatic symptoms, are common in MS patients. Aims: The present study aimed to examine and develop the efficacy of the Unified Transdiagnostic Protocol (UTP) in psychologically driven and, more specifically, the psychosomatic symptoms of MS patients. Methods: The present randomized clinical trial was conducted at the Brain and Neurology Clinic of Mohebe Mehr Hospital, Tehran, Iran, in 2022. In total, 43 MS patients were entered into the study and randomly assigned to two groups: intervention (n=21) and control (n=22). We implemented UTP in 12 weekly online sessions (each session took 60 minutes). Fatigue Severity Scale (FSS), Pittsburgh Sleep Quality Index (PSQI), and Larson Sexual Satisfaction Questionnaire (LSSQ) were used to assess psychosomatic symptoms. Results: Based on multivariate tests, there was a significant difference between different stages of the study, as well as the interaction effect between groups in terms of fatigue, desire to have sex, sexual attitude, sex life quality, sexual compatibility, and sleep quality (P<0.001). Moreover, there was a considerable difference in the changes in psychological symptom scores in UTP groups compared to control groups during the measurement stages (P<0.001). The stability of the treatment effects has been confirmed over time (P<0.001). Conclusion: As evidenced by the obtained results, UTP had stable effects on the treatment of psychosomatic symptoms. These include fatigue, desire to have sex, sexual attitude, sex life quality, sexual compatibility, and sleep quality, in MS patients.

Keywords: Cognitive Behavioral Therapy Multiple Sclerosis, Psychosomatic, Unified Transdiagnostic Protocol Symptoms
1. INTRODUCTION

Multiple sclerosis (MS) is defined as a chronic, progressive, neurodegenerative disorder of the central nervous system (Feinstein et al., 2019). Due to the physiopathology and unpredictable course of MS, psychological disorders are also among the typical characteristics of the disease (Henry et al., 2019). The likelihood of experiencing the symptoms of psychological disorders in MS patients is higher than that in healthy people and those with other chronic conditions (Grech et al., 2019). Maladaptive coping strategies and emotional dysregulation among MS patients are the strongest and most accurate predictors of suicidal ideation, as much as 85% (Feinstein and Pavisian, 2017).

In addition, comorbidities have an excess adverse effect on the patient’s mental health and are associated with an elevated risk of debilitating consequences, elevating the disease burden. For instance, risky behaviors in MS patients might expose them to various troublesome environmental agents (Hawkes and Boniface, 2014). Despite the high frequency of emotional disorders, comorbidities, and mental disorders in MS cases, these conditions are often overlooked, underdiagnosed, and undertreated (Skokou et al., 2012). Psychologically-driven manifestations, including psychosomatic symptoms, are common in MS patients and can lead to mental non-functionality over time (Nazari et al., 2020). MS patients have higher rates of psychologically-driven issues, resulting in numerous somatic complaints (i.e., sexual dysfunction, sexual dissatisfaction, sleep disorders, and fatigue) (Houtchens and Sadovnick, 2017; Nazari, 2020).

There could be multiple reasons behind this underdiagnosed condition. First of all, in the neurologic context, the evidence demonstrated that there are shortcomings concerning the application of DSM criteria (Strober and Arnett, 2015). The diverse complexity of the MS illness, as well as the possibility of mistaking specific physical complaints of MS, such as fatigue, sleep disorders, and sexual dissatisfaction, for depressive symptoms, might contribute to exaggerated underdiagnosis rates. Secondly, according to primary and secondary diagnoses, disorder-specific treatments are successful in complicated cases (Newby et al., 2015). Furthermore, when the clinical reality is intricately complex, and comorbidities are the norm, as is the case for a chronic somatic condition (e.g., MS), disorder-specific therapeutic measures might be hardly justifiable (Holmes et al., 2020). There are no established efficacious therapeutics for psychologically-driven problems in somatic diseases such as MS (Simpson et al., 2017).

Recent studies have indicated that Cognitive Behavioral Therapy (CBT) has been less effective than other psychological therapeutic approaches in the treatment of MS patients (Sesel et al., 2018). Integrated and transdiagnostic treatments have emerged as suggested ways for the treatment of a variety of coinciding psychosomatic issues since they guide a more efficient pathway in dealing with comorbidities (Clark et al., 2017; Norton and Paulus, 2016). The Unified Transdiagnostic Protocol (UTP) is a CBT transdiagnostic skill-based emotion-focused treatment (Barlow et al., 2017; Barlow et al., 2017b). The UTP has been detailed for the treatment of various psychologically driven symptoms, in which emotion dysregulation is the key component (Barlow et al., 2017). The results of many studies have confirmed the efficacy of UTP in the improvement of psychosomatic manifestations (i.e., sleep quality, sexual satisfaction, and fatigue) (Bullis et al., 2015). For psychosomatic symptoms, neuroticism has been a critical etiologic mechanism held in common by all emotional disorders (Brown and Barlow, 2009).

The UTP is deemed to be a gold-standard disorder-specific treatment approach for patients with comorbid emotional disorders (Barlow et al., 2017). The UTP, as a skill-based, emotion-focused interventional approach, could be of undeniable assistance given the high prevalence of psychologically-driven symptoms, increased comorbidities, recurring emotional problems, and the increased prevalence of risky behaviors in MS patients (Hawkes and Boniface, 2014). However, there is not enough practice-based data on the efficacy of UTP in the course of MS. Therefore, the present study aimed to examine and develop the efficacy of UTP in psychologically driven and, more specifically, the psychosomatic symptoms (fatigue, sleep disturbances, and sexual dysfunction) of MS patients.

2. METHOD

We conducted this randomized clinical trial on MS patients who were referred to the brain and neurology clinic of Imam Khomeini Hospital, Tehran, Iran, in 2022.

Inclusion and Exclusion Criteria

The inclusion criteria included a neurologist-confirmed diagnosis of the relapsing-remitting course of MS, an age range of at least 20 years, having a sexual relationship, proficiency in Persian language, stability in the type and dosage of the used medication three months before the commencement of the intervention, and participation in weekly appointments. On the other hand, the exclusion criteria entailed having severe psychiatric disorders (e.g., psychosis, bipolar disorder, substance abuse, severe depression or
anxiety, serious suicidal thoughts requiring the use of psychiatric medications), having a concurrent severe or chronic physical illness, changing the type or dosage of drugs during the treatment period, receiving concurrent psychological treatments, changing the physical or mental conditions disturbing the therapy, a history of epilepsy or developmental disorder, a history of undergoing psychological treatments, changing the marital or sexual activity status, failure to participate in more than two treatment sessions, and unwillingness to continue treatment.

Study Design, Participants, and Data
A total of 43 patients with MS, who fulfilled the inclusion criteria and whose diagnosis was confirmed by a neurologist, were selected by targeted sampling method from all the MS patients referring to the brain and neurology clinic. A CONSORT 2010 Flow Diagram presents the sampling process (Figure 1). We gathered the participants’ data, including baseline demographics, as well as all the data extracted from questionnaires regarding their psychosomatic symptoms (i.e., fatigue, sexual satisfaction, and sleep quality). Sexual satisfaction was further described by its components (desire to have sex, sexual attitude, sex life quality, and sexual compatibility).

The participants were assigned to two groups using a random allocation technique. In each stage - including the evaluation of the entry criteria and registration of participants, random allocation, and statistical data analysis - to avoid bias and administer blinding as much as possible, a different research assistant was asked for help. The groups remained unaware of each other’s existence. The Unified Transdiagnostic Treatment protocol was then implemented in the intervention group for 12 60-minute weekly sessions. Both groups completed a set of questionnaires for post-test evaluation and follow-up at the end of the treatment period, as well as one and three months after that. The participants had a very high degree of adherence, the protocol was well tolerated, and patients in the UTP group completed the treatment sessions and all post-treatment measures.

Definitions
Unified Transdiagnostic Protocol is a cognitive-behavioral therapy with an emphasis on emotional regulation. The treatment protocol includes eight main sections that target critical aspects of the processing and regulating emotional experiences: 1. Increasing motivation to participate in treatment, 2. Psychological training and tracking of emotional experiences, 3. Training awareness of emotion, 4. Cognitive evaluation, 5. Avoiding destructive emotions and behaviors arising from them, 6. Awareness of bodily sensations and tolerance of them, 7. Facing internal and external emotional triggers, 8. Preventing recurrence (Barlow et al., 2017).

Fatigue (or lethargy) refers to a state of weakening or depletion of one’s physical and/or mental resources, including a range of numbness caused by the over-activity of the muscles (Association, 1995). Sleep quality could be described by a wide spectrum of sleep-related measures, such as general sleep deficiency, delay in falling asleep, duration of decent sleep, sleep sufficiency, sleep disorders, the need for taking sleeping pills, feeling rested after sleep, and the morning performance after night sleep (Buysse et al., 1989). Sexual satisfaction could be defined by a variety of measures, including the desire for sexual relations, sexual attitude, quality of sex life, and sexual compatibility (Larson et al., 1998).

Data Collection Tools
Structured Clinical Interview for DSM-5 Disorders (SCID-5-CV)
DSM-5, is the most structured diagnostic tool used for the assessment of disorders. The evaluation of the validity and reliability of the clinical version of this tool showed that the percentage of favorable agreement between interview and clinical diagnosis was between 0.73 and 0.97, diagnostic sensitivity was 0.70, the rate of agreement between evaluators was above 0.75, and the Kappa level was 0.70 for most diagnoses (Osório et al., 2019). In a study conducted by the internal consistency, test-retest reliability, and the Kappa coefficient were 0.95-0.99, 0.60-0.79, and 0.57-0.72 for this instrument, respectively (Mohammadkhani et al., 2020). In the present study, this tool was used to evaluate the disorders mentioned in the exclusion criteria.
Figure 1 CONSORT 2010 Flow Diagram
**Fatigue Severity Scale (FSS)**
The FSS is a 9-item scale to measure fatigue severity in people with MS and lupus. It is the shortened form of the original 28-item fatigue intensity scale, which is graded from 1 (completely disagree) to 7 (completely agree), on a Likert scale. The scores of 9-18, 18-45, and >45 indicate low, moderate, and high fatigue levels, respectively. The designers confirmed the test-retest reliability and construct validity of the seven components: Scale, and Cronbach’s alpha was reported to be 0.81 for MS patients (Krupp et al., 1989). In reviewing the Persian version of this scale, confirmed its internal consistency and reported a Cronbach’s alpha coefficient of 0.96, which is very satisfactory (A’zimian et al., 2013). Salehpour et al., (2013) examined and confirmed the internal consistency, reliability, construct validity, as well as concurrent and predictive validity of this scale. The investigation of the predictive validity of this scale using multivariate regression showed that the scores obtained in this scale could predict the level of depression, anxiety, physical function, physical pain, and general health of patients (Salehpour et al., 2013).

**Pittsburgh Sleep Quality Index (PSQI)**
This index evaluates the subject’s sleep quality over the past month according to seven components, including subjective sleep quality (the individual’s experience of sleep quality), sleep latency (delay in falling asleep), sleep duration; getting enough sleep, sleep disturbances (night wakeups), the amount of sleep medication consumption, and finally, morning performance (problems caused by poor sleep during the day). The scoring of this index is from 0 (no problem) to 3 (severe problem) on a Likert scale. The minimum and maximum scores on this scale are 0 and 21. The scores 0, 1, 2, and 3 in each component indicate normal, mild, moderate, and severe sleep problems, respectively.

A total score of 6 or more signifies inadequate sleep. The researchers have investigated the clinical indicators of this index during 18 months in two populations of good sleepers (52 healthy samples) and bad sleepers (54 depressed patients and 62 patients with sleep disorders). Cronbach’s alpha coefficient of 0.83 and validity and retest reliability of 0.85 confirmed the internal consistency of this index. It also obtained a total score of more than 5 with a kappa coefficient of 0.75, a specificity of 86.5%, and a diagnostic sensitivity of 89.6%, indicating its power for differentiating good sleepers from bad sleepers (Buysse et al., 1989). Different studies confirmed the reliability and validity of the Persian version of the index (Farahbakhsh and Dehghani, 2016; Shafaat et al., 2017).

**Larson Sexual Satisfaction Questionnaire (LSSQ)**
This 25-item questionnaire evaluates four components: the desire to have sex, sexual attitude, sex life quality, and sexual compatibility. The questionnaire is scored on a Likert scale from 1 (never) to 5 (always). The score ranges of 25-41, 42-84, and above 84 indicate low, moderate, and high sexual satisfaction, respectively. The Cronbach’s alpha coefficient of 0.91 and test-retest reliability of 0.93 confirmed the internal consistency of this scale (Larson et al., 1998). Bahrami et al., (2016) investigated the 4-factor design of the Persian version of this questionnaire using confirmatory factor analysis. Cronbach’s alpha coefficient of more than 0.70 confirmed the internal stability of the scale (Bahrami et al., 2016).

**Statistical Analysis**
We analyzed data using SPSS software (version 24) through student’s t-test and two-way repeated measures analysis of variance (ANOVA). We used the Kruskal-Walli’s and Mann-Whitney U tests to assess the variables with non-normal distribution. The ANOVA was conducted with a mixed model using both within-subject and between-subject designs to determine the impact of the UTP on all reported measures. We tested the homogeneity of variances, normal distribution of scores, and the sphericity using the Levene’s test, the Kolmogorov-Smirnov test, and the Mauchly’s test, respectively. The level of significance was less than 0.05 (P< 0.05).

**Ethical considerations**
The researchers registered the study in the Iranian Registry of Clinical Trials (IRCT20221230056986N1). Before the commencement of the study, the participants were informed of the study objectives and assured of data confidentiality. All participants signed the informed written consent. The Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (Ethics code: IR.SBMU.MSP.REC.1398.669) approved the study protocol.
3. RESULTS
A total of 43 MS patients participated in this study, of which 22 cases (51.2%) were in the intervention group and 21 others (48.8%) were in the control group. Patients in both groups were homogeneous in terms of demographic features, including age, gender, and education. Table 1 and Figure 2 present the mean scores of psychosomatic symptoms in three stages of measurement divided by study group. There was no significant change in the control group in the mean scores in the pre-test compared to the post-test and follow-up stages. In the experimental group, on the other hand, we observed a decrease in the mean scores in the post-test and follow-up stages compared to the pre-test stage. There was a significant difference, based on multivariate tests, between different stages of the study, the interaction effect between groups in terms of fatigue, desire to have sex, sexual attitude, sex life quality, sexual compatibility, and sleep quality, (P<0.001) (Table 1).

Figure 2 The mean scores of psychosomatic symptoms in three stages of measurement compared between the Control group and UTP group
A weak correlation has been reported between sexual satisfaction and quality sleep in MS patients (r=0.41, P=0.006). Fatigue had a reverse weak correlation with quality sexual satisfaction (r=−0.48, P<0.001) and a reverse moderate

The results of the univariate (within-subject effects) test for the comparison of psychosomatic symptoms in the control and UTP groups are presented in (Table 2). Our findings indicated that the F values associated with the interaction effects between groups and repeated measures for all psychological symptoms were significant at a significance level of 0.01 (P<0.01). The significance of the interaction effects highlights the fact that there are statistically considerable differences between the changes in psychological symptom scores reported for the groups of control and UTP during the measurement stages.

**Table 1** Mean of psychosomatic symptoms' scores in three stages of measurement divided by study group

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control</th>
<th>Intervention</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-test</td>
<td>Post-test</td>
<td>Follow-up</td>
<td>Pre-test</td>
<td>Post-test</td>
</tr>
<tr>
<td>Fatigue</td>
<td>36.71 ± 2.85</td>
<td>37.62 ± 2.42</td>
<td>37.38 ± 1.96</td>
<td>37.09 ± 2.35</td>
<td>33.23 ± 2.18</td>
</tr>
<tr>
<td>Sexual Satisfaction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desire to Have Sex</td>
<td>13.95 ± 2.73</td>
<td>14.52 ± 2.68</td>
<td>14.38 ± 2.52</td>
<td>14.23 ± 2.49</td>
<td>17.55 ± 2.99</td>
</tr>
<tr>
<td>Sexual Attitude</td>
<td>15.14 ± 3.78</td>
<td>15.71 ± 3.51</td>
<td>15.43 ± 3.80</td>
<td>15.05 ± 3.68</td>
<td>18.73 ± 3.47</td>
</tr>
<tr>
<td>Sex Life Quality</td>
<td>19.76 ± 2.74</td>
<td>20.07 ± 2.38</td>
<td>19.50 ± 2.72</td>
<td>20.41 ± 2.67</td>
<td>23.50 ± 3.00</td>
</tr>
<tr>
<td>Total Sexual Satisfaction</td>
<td>65.52 ± 7.17</td>
<td>64.01 ± 6.83</td>
<td>63.74 ± 7.31</td>
<td>64.23 ± 8.25</td>
<td>78.91 ± 8.50</td>
</tr>
<tr>
<td>Sleep Quality</td>
<td>13.62 ± 2.44</td>
<td>13.14 ± 2.43</td>
<td>12.95 ± 2.48</td>
<td>13.55 ± 1.87</td>
<td>9.77 ± 1.66</td>
</tr>
</tbody>
</table>

The results of the univariate within-subject effects test to compare the psychosomatic symptoms of the control and UTP groups

<table>
<thead>
<tr>
<th>The Source of Effect</th>
<th>Repeated Measure</th>
<th>Interaction between Groups and Repeated Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>P-value</td>
<td>Effect Size</td>
</tr>
<tr>
<td>Fatigue</td>
<td>The Greenhouse-Geisser</td>
<td>8.947</td>
</tr>
<tr>
<td></td>
<td>The Huynd-Feldt</td>
<td>8.947</td>
</tr>
<tr>
<td>Desire to Have Sex</td>
<td>Sphericity Assumed</td>
<td>39.208</td>
</tr>
<tr>
<td></td>
<td>Lower-bound</td>
<td>39.208</td>
</tr>
<tr>
<td>Sexual Attitude</td>
<td>Sphericity Assumed</td>
<td>40.729</td>
</tr>
<tr>
<td></td>
<td>Lower-bound</td>
<td>40.729</td>
</tr>
<tr>
<td>Sex Life Quality</td>
<td>The Greenhouse-Geisser</td>
<td>30.362</td>
</tr>
<tr>
<td></td>
<td>The Huynd-Feldt</td>
<td>30.362</td>
</tr>
<tr>
<td>Sexual Compatibility</td>
<td>Sphericity Assumed</td>
<td>23.392</td>
</tr>
<tr>
<td></td>
<td>Lower-bound</td>
<td>23.392</td>
</tr>
<tr>
<td>Sleep Quality</td>
<td>Sphericity Assumed</td>
<td>21.405</td>
</tr>
<tr>
<td></td>
<td>Lower-bound</td>
<td>21.405</td>
</tr>
</tbody>
</table>

Furthermore, to compare the mean scores during the measurement stages, Bonferroni’s post hoc test was used. The pairwise comparisons presented in Table 3 indicate the difference in the scores of psychosomatic symptoms during the treatment stages in the control and UTP groups. Considering the results obtained in the UTP group, the difference between the mean scores of the pre-test stage and those obtained in the post-test and follow-up stages was statistically significant (P<0.05). The follow-up scores decreased significantly compared to the pre-test stage. The difference between the scores reported in the post-test and follow-up stages was not statistically significant (P>0.05), indicating the stability of the treatment effects over time.

There was no statistically significant difference in the control group between the scores of the pre-test stage and those in the post-test and follow-up stages. The difference between the scores of the post-test and follow-up stages was not statistically significant (P>0.05). A weak correlation has been reported between sexual satisfaction and quality sleep in MS patients (r=0.41, P=0.006). Fatigue had a reverse weak correlation with quality sexual satisfaction (r=−0.48, P<0.001) and a reverse moderate

---

Medical Science 27, e353ms3204 (2023) 7 of 12
correlation with quality sleep (r=0.61, P<0.005) in MS patients. Logistic regression showed that quality of sleep was a predictor of fatigue (β=1.51; P=0.02), while sexual satisfaction could not predict the value of fatigue (β=0.94; P=0.76).

Table 3 Post hoc Bonferroni test

<table>
<thead>
<tr>
<th>Variables</th>
<th>UTP group</th>
<th></th>
<th>Control Group</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Proximal Stage</td>
<td>Distal Stage</td>
<td>The Difference of means</td>
<td>Standard Error</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Pre-test</td>
<td>Post-test</td>
<td>3.864</td>
<td>0.435</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up</td>
<td>3.409</td>
<td>0.567</td>
</tr>
<tr>
<td></td>
<td>Post-test</td>
<td>Follow-up</td>
<td>-0.455</td>
<td>0.617</td>
</tr>
<tr>
<td>Desire to Have Sex</td>
<td>Pre-test</td>
<td>Post-test</td>
<td>-3.318</td>
<td>0.298</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up</td>
<td>-2.682</td>
<td>0.349</td>
</tr>
<tr>
<td></td>
<td>Post-test</td>
<td>Follow-up</td>
<td>0.636</td>
<td>0.326</td>
</tr>
<tr>
<td>Sexual Attitude</td>
<td>Pre-test</td>
<td>Post-test</td>
<td>-3.682</td>
<td>0.329</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up</td>
<td>-2.909</td>
<td>0.377</td>
</tr>
<tr>
<td></td>
<td>Post-test</td>
<td>Follow-up</td>
<td>0.773</td>
<td>0.320</td>
</tr>
<tr>
<td>Sex Life Quality</td>
<td>Pre-test</td>
<td>Post-test</td>
<td>-3.091</td>
<td>0.352</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up</td>
<td>-2.582</td>
<td>0.328</td>
</tr>
<tr>
<td></td>
<td>Post-test</td>
<td>Follow-up</td>
<td>0.509</td>
<td>0.244</td>
</tr>
<tr>
<td>Sexual Compatibility</td>
<td>Pre-test</td>
<td>Post-test</td>
<td>-4.591</td>
<td>0.568</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up</td>
<td>-3.573</td>
<td>0.559</td>
</tr>
<tr>
<td></td>
<td>Post-test</td>
<td>Follow-up</td>
<td>1.018</td>
<td>0.454</td>
</tr>
<tr>
<td>Sleep Quality</td>
<td>Pre-test</td>
<td>Post-test</td>
<td>3.773</td>
<td>0.451</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up</td>
<td>3.273</td>
<td>0.513</td>
</tr>
<tr>
<td></td>
<td>Post-test</td>
<td>Follow-up</td>
<td>-0.500</td>
<td>0.550</td>
</tr>
</tbody>
</table>

4. DISCUSSION

As evidenced by the results of this study, 12 60-minute weekly sessions of UTP had a statistically significant effect on fatigue, desire to have sex, sexual attitude, sex life quality, sexual compatibility, and sleep quality in MS patients. Different studies have confirmed the stability of the treatment effects of UTP over time. In this study, we followed the development of the emotion regulation mechanism outlined in the unified transdiagnostic protocol treatment framework, by which fundamental underlying factors aim to enhance the quality of care and life of patients with MS. We unveiled that MS patients with undergoing UTP experienced lower fatigue intensity, improved sleep quality, and more sexual satisfaction as a result of becoming more emotionally-regulated.

Nevertheless, we found no similar study assessing the effectiveness of UTP in psychosomatic symptoms, including fatigue, sexual dysfunction, and sleep quality, in MS patients to reject or confirm the present findings. The fatigue associated with MS is one of the most common symptoms of patients with this disease, particularly in its early stages (Krupp et al., 2010). Approximately 80% of patients with MS reported fatigue, and more than 55% of patients considered it the worst symptom of their condition (Iriarte et al., 2000). The studies have demonstrated that as the occurrence of fatigue elevates in MS patients, their overall disability increases and their physical and psychological quality of life decreases (Latimer-Cheung et al., 2013).

Fatigue has an association with depression, anxiety, sleep quality, and sexual dysfunction in patients with MS. Although some studies have recommended psychological interventions, including meditation and cognitive-behavioral therapy for the management of fatigue in these patients Asano and Finlayson, (2014), Chalah et al., (2019), Darija et al., (2015), Siengsukon et al., (2018), the supporting evidence has not been strong enough. The results of the present study pinpointed that the patients who received UTP treatment reported lower measures of physical fatigue. Studies confirmed an improvement in fatigue after transdiagnostic treatment (Ellard et al., 2012; Hara et al., 2018). However, none of these studies focused on patients with MS; therefore, future studies can provide more evidence in this respect.
Sleep disturbances are common in MS, and polysomnography studies indicate changes in the micro and macro structures of sleep-in patients with this disease (Neau et al., 2012). Sleep disturbances in MS can be secondary to multiple symptoms of the disease or have a primary cause. There are bidirectional relationships between sleep disturbance and the worsening of MS symptoms Fleming and Pollak, (2005) and also a bidirectional relationship between sleep disturbance and depression, which causes a decrease in the quality of life in MS patients (Trojan et al., 2012). Sleep disturbance is also associated with more fatigue in these patients (Braley and Boudreau, 2016). The evaluation of sleep quality can provide reliable diagnostic information related to the relapsing-remitting course of MS. It has been suggested that integrated interventions in the treatment of patients with MS could help improve sleep disturbances (Harvey, 2009).

Therefore, these therapeutic measures should simultaneously target other areas, such as depression and anxiety, other than sleep quality, all of which could be targeted by UTP treatment. This signifies that UTP treatment for sleep disturbances in MS patients could fulfill such a goal (Buratti et al., 2019, De-la-Vega et al., 2019). Accordingly, our findings demonstrated that MS cases who received UTP treatment developed objectively higher quality of sleep during their treatment. The other results of the present study confirmed the role of UTP in improving sexual dysfunction in MS patients. Sexual dysfunction, as one of the other most common symptoms reported by MS patients, has been observed in about 40%-80% of them (Gromisch et al., 2016). In addition to cortical and spinal lesions associated with MS, psychological and social problems, and physical complications, such as excretion problems and convulsive states, could all lead to sexual dysfunction (Cordeau and Courtois, 2014; Fragalà et al., 2014, Sanders et al., 2000; Winder et al., 2016). In addition, sexual dysfunction is robustly associated with depression, anxiety, and sleep problems (Crayton et al., 2004; Young et al., 2017).

Despite the importance of sexual dysfunction in MS, these symptoms are often overlooked. This can worsen the number and severity of symptoms and affect multiple aspects of mental health and quality of life in these patients (Foley and Beier, 2006; Schairer et al., 2014). It is worth mentioning that psychological-based interventions, namely UTP, are capable of improving sexual dysfunction and subsequently increasing the quality of life for these patients (Schairer, 2015). Similarly, the present study demonstrated that MS patients treated with UTP had markedly lower rates of sexual dysfunction compared to their peers who did not receive UTP. In line with our study, based on the study conducted by De-Ornelas-Maia et al., (2017) sessions of UTP lead to marked improvements in one’s quality of life, anxiety, and depression in those with mental disorders.

All in all, to understand why UTP drastically impacts somatic complaints in MS patients, one must notice that the occurrence of psychosomatic symptoms (i.e., fatigue, sleep disturbances, and sexual dysfunction) are all intricately intertwined with each other while also being closely interwoven with psychologic symptoms in MS patients. As previously mentioned, there have been multiple accounts of bidirectional correlations of MS severity with fatigue, depression, and sleep disturbances (Braley and Boudreau, 2016; Chalah et al., 2019; Fleming and Pollak, 2005; Trojan et al., 2012). Therefore, an integrated therapeutic measure that could influence all the components in this interlaced network of symptoms could substantially improve them and enhance the quality of life in MS patients; this is what the UTP treatment does.

5. CONCLUSION
It seems that 12 sessions of UTP had a stable effect on treating psychosomatic symptoms, including fatigue, desire to have sex, sexual attitude, sex life quality, sexual compatibility, and sleep quality in MS patients. The findings of this study supported the notion that the UTP could be an additional efficient therapeutic measure as a financially optimal transdiagnostic treatment of psychosomatic symptoms in adult MS patients. The UTP is as equally efficacious as gold-standard disorder-specific protocols in MS patients. Nonetheless, additional analysis is required to expand the findings obtained in this study. Transdiagnostic research can better present the clinical and scientific reality of psychosomatic problems and reflect the complexity and comorbidity that is the norm in clinical practice.

Acknowledgment
We thank the participants who contributed samples to the study. The authors extend their gratitude to the Brain and Neurology Clinic of Moheb Mehr Hospital for their collaboration in data collection.

Author Contributions
Amir Mahdi Katani (data collection and writing), Abbas Masjedi Arani (analysis), Reza Hajmanouchehri (Data collection), Banafsheh Mohajerin (Data collection)
Ethical approval
The Medical Ethics Committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran (Ethical approval code: IR.SBMU.MSP.REC.1398.669) approved the study protocol.

Informed consent
Before the start of the study, informed written Oral informed consent was obtained from all participants included in the study.

Funding
This study was funded by Shahid Beheshti University of Medical Sciences (Grant Number: 20180)

Conflict of interest
The authors declare that there is no conflict of interests.

Data and materials availability
All data sets collected during this study are available upon reasonable request from the corresponding author.

REFERENCES AND NOTES

1_suppl_5.s12


47. Schairer LC. Pilot Randomized Control Trial of a Brief Multidisciplinary Consultation Intervention for Treating Sexual Dysfunction in MS, Yeshiva University 2015.


